AGP

9MCY22 Result Review: BUY Stance Maintained



Equity Research | Pharmaceuticals | Friday, 21 October, 2022

AGP has announced its 9MCY22 result where it posted profit after tax of Rs981mn (EPS: Rs3.5) as compared to profit after tax of Rs1,019mn (EPS: Rs3.64) in the same period last year, down by 3.8% YoY due to higher effective taxation.

The company has posted a revenue of Rs7.22bn against Rs5.20bn in SPLY, recording a growth of 38.9% YoY. We note that this surge is attributed to the increase in local volumetric sales.

The gross margin has been decreased to 51.4% as compared to 53.9% during SPLY on account of higher input cost related to devaluation of rupee, domestic inflation and logistical cost.


SG&A expenses have been increased by 46.7% YoY to Rs2.11bn as compared to Rs1.44bn during SPLY. Finance cost has increased by 15.3% YoY to Rs84mn as compared to Rs73mn during SPLY.

Lastly, the effective taxation has been increased to 31.5% as compared to 17.1% during SPLY.

AGP is currently trading at CY23E PE of 12.26x. Further, the scrip is also trading at CY23E PB of 1.97x which offers a discount of 17% relative to its 3-year historical average of 2.38. We have a **BUY** stance on the scrip with a DCF based Jun-23 TP of Rs90 which provides an upside potential of 15%. Furthermore, it also offers a dividend yield of 3.5% which makes a total return of 18.5%.

Rupees' millions	3QCY22	3QCY21	YoY	9MCY22	9MCY21	YoY
Net Sales	2,319	1,547	49.8% ▲	7,218	5,195	38.9% ▲
Cost of Sales	1,191	710	67.9% ▲	3,510	2,396	46.5% ▲
Gross Profit	1,127	838	34.6% ▲	3,708	2,799	32.5% ▲
SG&A Expenses	748	498	50.4% ▲	2,107	1,436	46.7% ▲
Other Expenses	62	37	65.6% ▲	202	101	100.2% ▲
Operating Profit	317	303	4.7% ▲	1,399	1,262	10.9% ▲
Other Income	18	7	134.9% ▲	116	41	184.2% ▲
Finance Cost	41	20	106.0% ▲	84	73	15.3% ▲
Profit Before Taxation	293	290	1.1% ▲	1,431	1,230	16.4% ▲
Taxation	59	43	38.1% ▲	450	211	113.8% ▲
Profit After Taxation	234	247	5.3% ▼	981	1,019	3.8% ▼
Earnings Per Share	0.83	0.88	5.3% ▼	3.50	3.64	3.8% ▼
Dividend	0.00	0.00		0.00	0.00	
Bonus	0%	0%		0%	0%	
Gross Margin	48.6%	54.1%	5.5% ▼	51.4%	53.9%	2.5% ▼
SG&A Expenses to Sales	32.3%	32.2%	0.1% 🛦	29.2%	27.6%	1.5% ▲
Other Expenses to Sales	2.7%	2.4%	0.3% ▲	2.8%	1.9%	0.9% ▲
Other Income to Sales	0.8%	0.5%	0.3% ▲	1.6%	0.8%	0.8% ▲
Effective Taxation	20.3%	14.9%	5.4% ▲	31.5%	17.1%	14.3% ▲
Net Margin	10.1%	16.0%	5.9% ▼	13.6%	19.6%	6.0% ▼

Source: ACPL Research, Company Financials



Financial Projections

Rupees' millions	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E	CY26E
Net sales	6,946	7,420	9,685	10,847	12,156	13,632	15,299
Cost of sale	3,086	3,303	4,710	5,143	5,764	6,464	7,254
Gross profit	3,861	4,117	4,975	5,704	6,392	7,169	8,045
Administration expenses	227	391	388	435	487	547	613
Marketing and selling expenses	1,404	1,615	2,421	2,712	3,039	3,408	3,825
Other operating expenses	183	157	276	309	346	389	436
Operating Profit	2,047	1,955	1,889	2,248	2,519	2,825	3,171
Other operating income	32	46	155	174	194	218	245
Finance cost	152	89	112	220	230	241	252
Profit before taxation	1,927	1,911	1,933	2,202	2,484	2,802	3,164
Taxation	339	346	608	416	469	529	597
Profit after taxation	1,587	1,565	1,324	1,786	2,015	2,273	2,566
EPS	5.67	5.59	4.73	6.38	7.20	8.12	9.17

Source: ACPL Research, Company Financials

Horizontal Analysis

	CY20A	CY21A	CY22E	CY23E	CY24E	CY25E	CY26E
Net sales	11.1%	6.8%	30.5%	12.0%	12.1%	12.1%	12.2%
Cost of sale	19.0%	7.0%	42.6%	9.2%	12.1%	12.1%	12.2%
Gross profit	5.5%	6.6%	20.8%	14.6%	12.1%	12.1%	12.2%
Administration expenses	43.6%	72.4%	-0.6%	12.0%	12.1%	12.1%	12.2%
Marketing and selling expenses	8.5%	15.0%	49.9%	12.0%	12.1%	12.1%	12.2%
Other operating expenses	9.7%	-14.2%	75.6%	12.0%	12.1%	12.1%	12.2%
Operating Profit	0.3%	-4.5%	-3.3%	19.0%	12.1%	12.1%	12.2%
Other operating income	180.4%	46.0%	236.0%	12.0%	12.1%	12.1%	12.2%
Finance cost	-33.1%	-41.2%	25.2%	96.5%	4.8%	4.8%	4.4%
Profit before taxation	5.6%	-0.8%	1.1%	13.9%	12.8%	12.8%	12.9%
Taxation	-10.3%	2.1%	75.5%	-31.6%	12.8%	12.8%	12.9%
Profit after taxation	9.8%	-1.4%	-15.4%	34.9%	12.8%	12.8%	12.9%
EPS	9.8%	-1.4%	-15.4%	34.9%	12.8%	12.8%	12.9%

Source: ACPL Research, Company Financials

Abbasi and Company (Pvt.) Ltd.

Key Ratios

Profitability Ratios		CY20A	CY21A	CY22E	CY23E	CY24E	CY25E	CY26E
GP Margin	%	55.58	55.49	51.37	52.59	52.59	52.59	52.59
NP Margin	%	22.85	21.09	13.68	16.47	16.57	16.67	16.78
OP Margin	%	29.47	26.34	19.51	20.73	20.73	20.73	20.73
ROE	%	19.33	16.48	13.13	16.08	16.50	16.92	17.25
ROCE	%	18.28	16.22	12.89	15.92	16.35	16.79	17.13
ROA	%	15.58	13.97	10.38	11.82	11.58	11.36	11.18
Linuidita Datina		CV20A	CV24 A	CV22F	CV22F	CV24F	CV2FF	CV2CE
Liquidity Ratios		CY20A	CY21A	CY22E	CY23E	CY24E	CY25E	CY26E
Current	Х	1.71	1.65	3.15	3.27	3.92	4.48	5.03
Acid-test	Х	1.25	1.34	1.97	1.54	1.58	1.58	1.59
Cash to current liab.	X	0.25	0.21	1.05	1.63	2.24	2.80	3.34
Activity Ratios		CY20A	CY21A	CY22E	CY23E	CY24E	CY25E	CY26E
Inventory Turnover	х	3	3	3	3	3	3	3
Inventory Days		140	121	121	121	121	121	121
Receivables Days		39	40	34	32	32	32	32
Payables Days		99	118	130	130	130	130	130
Operating Cycle		80	44	25	23	23	23	23
Leave to the Ballion		CV20A	CV24.4	0,4225	0,4325	0/245	OV255	CV2CE
Investment Ratios		CY20A	CY21A	CY22E	CY23E	CY24E	CY25E	CY26E
EPS	Rs.	5.67	5.59	4.73	6.38	7.20	8.12	9.17
DPS	Rs.	2.00	2.50	2.00	2.75	3.25	3.75	4.00
Div. Yield	%	2.56	3.20	2.56	3.52	4.15	4.79	5.11
Dividend Cover	X	2.83	2.24	2.37	2.32	2.21	2.16	2.29
BVPS	Rs.	29.32	33.91	36.04	39.67	43.61	47.98	53.15
Payout	%	35.28	44.73	42.28	43.11	45.17	46.19	43.64
Retention	%	64.72	55.27	57.72	56.89	54.83	53.81	56.36
No. of Shares	mn	280	280	280	280	280	280	280
P/E		13.80	14.00	16.54	12.26	10.87	9.63	8.53
Sales per share		24.81	26.50	34.59	38.74	43.41	48.69	54.64
P/BV		2.67	2.31	2.17	1.97	1.79	1.63	1.47
Price to Sales		3.64	3.40	2.61	2.33	2.08	1.85	1.65
Gearing Ratios		CY20A	CY21A	CY22E	CY23E	CY24E	CY25E	CY26E
Debt to Equity	х	12.97	10.41	1.09	0.31	0.23	0.17	0.07
Interest Cover								

Source: ACPL Research, Company Financials

Abbasi and Company (Pvt.) Ltd.

This report has been prepared by Abbasi & Company (Private) Limited and is provided for information purposes only. Under no circumstances, this is to be used or considered as an offer to sell or solicitation of any offer to buy. While reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. From time to time, Abbasi & Company (Private) Limited and or any of its officers or directors may, as permitted by applicable laws, have a position, or otherwise be interested in any transaction, in any securities directly or indirectly subject of this report. This report is provided only for the information of professional advisers who are expected to make their own investment decisions without undue reliance on this report. Investments in capital markets are subject to market risk and Abbasi & Company (Private) Limited accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. In particular, the report takes no account of the investment objectives, financial situation and needs of investors, who should seek further professional advice or rely upon their own judgment and acumen before making any investment. The views expressed in this report are those of Abbasi & Company (Private) Limited Research Department and do not necessarily reflect those of the company or its directors. Abbasi & Company (Private) Limited as a firm may have business relationships, including investment--banking relationships, with the companies referred to in this report. Abbasi & Company (Private) Limited does not act as a market maker in the securities of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives do not have a financial interest in the securities of the subject company to an amount exceeding 1% of the value of the securities of the subject company at the time of issuance of this report. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives are not currently serving or have served in the past three years as a director or officer of the subject company. Abbasi & Company (Private) Limited or any officers, directors, associates or close relatives have not received compensation from the subject company in the previous 12 months. The subject company currently is not, or during the 12-month period preceding the date of publication or distribution of this report, was not, a client of Abbasi & Company (Private) Limited. We have not managed or co-managed a public offering or any take-over, buyback or delisting offer of securities for the subject company in the past 12 months and/or received compensation for corporate advisory services, brokerage services or underwriting services from the subject company in the past 12 months. Abbasi & Company (Private) Limited does not expect to receive or intend to seek compensation for corporate advisory services or underwriting services from the subject company in the next 3 months

All rights reserved by Abbasi & Company (Private) Limited. This report or any portion hereof may not be reproduced, distributed or published by any person for any purpose whatsoever. Nor can it be sent to a third party without prior consent of Abbasi & Company (Private) Limited. Action could be taken for unauthorized reproduction, distribution or publication

VALIDITY OF THE PUBLICATION OR REPORT

The information in this publication or report is, regardless of source, given in good faith, and may only be valid as of the stated date of this publication or report. The information may be subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company, jurisdiction or financial instruments referred to in this report. The valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report and were based upon several estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein is not to be relied upon as a representation and/or warranty by Abbasi & Company (Private) Limited and/or its other associated and affiliated companies, that:

- I. Such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- II. There is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein

DEFINITION OF TERMS

TP	Target Price	CAGR	Compound Annual Growth Rate	FCF	Free Cash Flows
FCFE	Free Cash Flows to Equity	FCFF	Free Cash Flows to Firm	DCF	Discounted Cash Flows
PE	Price to Earnings Ratio	PB	Price to Book Ratio	BVPS	Book Value Per Share
EPS	Earnings Per Share	DPS	Dividend Per Share	ROE	Return of Equity
ROA	Return on Assets	SOTP	Sum of the Parts	LDCP	Last Day Closing Price

VALUATION METHODOLOGY

To arrive at our Target Price, Abbasi & Company (Private) Limited uses different valuation methods which include:

- I. Discounted Cash Flow Model
- II. Dividend Discount Model
- III. Relative Valuation Model
- IV. Sum of Parts Valuation

RATINGS CRITERIA

Abbasis & Company (Private) Limited employs a three-tier ratings system to rate a stock and sector, as mentioned below, which is based upon the level of expected return for a specific stock and outlook of sector. The rating is based on the following with stated time horizon

Stock Rating	Expected Total Return
BUY	Greater than 15%
HOLD	Between -5% to 15%
SELL	Less than and equal to -5%

Sector Rating	Sector Outlook
Overweight	Positive
Market Weight	Neutral
Underweight	Negative

Ratings are updated to account for any development impacting the economy/sector/company, changes in analysts' assumptions or a combination of these factors.

RESEARCH DISSEMINATION POLICY

Abbasi & Company (Private) Limited endeavors to make all reasonable efforts to disseminate research to all eligible clients in a timely manner through either physical or electronic distribution such as email, fax mail etc. Nevertheless, all clients may not receive the material at the same time

OTHER DISCLOSURES

The research analyst is primarily involved in the preparation of this report, certifies that:

- I. The views expressed in this report accurately reflect his/her personal views about the subject company/stock /sector and economy
- II. No part of his/her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report

The Research Analyst is not and was not involved in issuing of a research report on any of the subject company's associated companies

RESEARCH DEPARTMENT

6 - Shadman, Lahore

Phone: (+92) 42 38302028; Ext 116, 117 Email: research@abbasiandcompany.com web: www.abbasiandcompany.com

HEAD OFFICE

6 - Shadman, Lahore

Phone: (+92) 42 38302028

Email: info@abbasiandcompany.com web: www.abbasiandcompany.com